You are here

  • Home
  • Archive
  • Volume 70, Issue 1
  • Which intravenous bronchodilators are being administered to children presenting with acute severe wheeze in the UK and Ireland?

Article Text

Article menu

Download PDFPDF

Chest clinic
Audit, research and guideline update
Which intravenous bronchodilators are being administered to children presenting with acute severe wheeze in the UK and Ireland?
  1. I Morris1,
  2. M D Lyttle2,3,
  3. R O'Sullivan4,
  4. N Sargant2,
  5. I J M Doull5,
  6. C V E Powell1,6
  7. on behalf of the PERUKI network
  1. 1Department of General Paediatrics, Children's Hospital for Wales, Cardiff, UK
  2. 2Paediatric Emergency Department, Bristol Royal Hospital for Children, Bristol, UK
  3. 3Academic Department of Emergency Care, University of the West of England, Bristol, UK
  4. 4Department of Emergency Medicine, Cork University Hospital, Cork, Ireland
  5. 5Department of Paediatric Respiratory Medicine, Children's Hospital for Wales, Cardiff, UK
  6. 6Institute of Molecular and Experimental Medicine, Cardiff University, School of Medicine, Cardiff, UK
  1. Correspondence to Dr Colin V E Powell, Department of Child Health, Children's Hospital for Wales, Cardiff; Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff CF14 4XW, UK; powellc7{at}cardiff.ac.uk

Abstract

During a prospective 10-week assessment period, 3238 children aged 1–16 years presented with acute wheeze to Paediatric Emergency Research in the UK and Ireland centres. 110 (3.3%) received intravenous bronchodilators. Intravenous magnesium sulfate (MgSO4) was used in 67 (60.9%), salbutamol in 61 (55.5%) and aminophylline in 52 (47.3%) of cases. In 35 cases (31.8%), two drugs were used together, and in 18 cases (16.4%), all three drugs were administered. When used sequentially the most common order was salbutamol, then MgSO4, then aminophylline. Overall, 30 different intravenous treatment regimens were used varying in drugs, dose, rate and duration.

  • Asthma
  • Asthma Guidelines
  • Asthma Pharmacology
  • Paediatric asthma
View Full Text

http://dx.doi.org/10.1136/thoraxjnl-2014-206041

Statistics from Altmetric.com

    View Full Text

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions